Market – Page 2

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

3 months ago talkbio0Tagged Direct-to-Consumer, discount, eli lilly, Glucagon-Like Peptide 1, Growth, LillyDirect, Market, Pricing, Sales - occupational activity, Sharing (Social Behavior), Walmart Pharmacy, Weight maintenance regimen, Zepbound

Zepbound; Eli Lilly; LillyDirect; direct-to-consumer; Walmart Pharmacy; GLP-1; weight management; discount pricing; market share; sales growth

United Imaging Healthcare Q3 2025 Results: Overseas Revenue Up 42% YoY

3 months ago talkbio0Tagged Global Expansion, Investments, Market, Medical Imaging, overseas, Q3, revenue growth, United Imaging Healthcare

United Imaging Healthcare; Q3 2025 results; overseas revenue growth; medical imaging; emerging markets; R&D investment; global expansion

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

3 months ago talkbio0Tagged Biological Factors, conditions, Dilution technique, Gross (qualifier value), Immunology, Market, Pricing, public entity, RAPT

RAPT Therapeutics; public offering; common stock; underwritten offering; biopharmaceutical; immunology; market conditions; share dilution; offering pricing; gross proceeds

Unlocking Access: Navigating Pharma’s Regulatory Crossroads – Recent Updates (2025)

4 months ago talkbio0Tagged Access, access strategy, Biosimilars, CRLs, drug importation, drug price, executive actions, Market, Patient access, pharmaceutical regulation, United States Food and Drug Administration

pharmaceutical regulation; market access; drug pricing; FDA transparency; biosimilars; executive actions; market access strategy; drug importation; CRLs; patient access

Recent News: Gain Peace of Mind with the Lentiviral Experts

4 months ago talkbio0Tagged advanced manufacturing, Biological Factors, CAR-T therapy, gene therapy, Growth, immuno-oncology, lentiviral vectors, Market, regulatory approval

lentiviral vectors; CAR-T therapy; gene therapy; biologics; immuno-oncology; market growth; advanced manufacturing; regulatory approval

AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.

5 months ago talkbio0Tagged AbbVie, exclusivity extension, Generic competition, Market, Patent Settlement, pharmaceutical litigation, Rinvoq, U.S., upadacitinib

AbbVie; Rinvoq; patent settlement; generic competition; exclusivity extension; upadacitinib; US market; pharmaceutical litigation

Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless

5 months ago talkbio0Tagged asset, Exit, Lundbeck, Market, neuro-rare diseases, neuro-specialty diseases, NewBridge Pharmaceuticals, offloading, partnerships, restructuring, Swixx Group, Zuellig Pharma

Lundbeck; market exit; asset offloading; partnerships; job cuts; Swixx Group; Zuellig Pharma; NewBridge Pharmaceuticals; restructuring; neuro-rare diseases; neuro-specialty diseases

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

5 months ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, DualityBio, HER2-positive carcinoma of breast, Market, Oncology Pipeline, pamirtecan, Phase 3 trial, Progression-Free Survival, trastuzumab

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market

Sanofi Phase 3 Eczema Win Falls Short of Analyst Expectations

5 months ago talkbio0Tagged Amlitelimab, Dermatitis, Atopic, Dupixent, EASI-75, Eczema, Expectations, Market, Reaction, sanofi

Sanofi; amlitelimab; phase 3 trial; eczema; atopic dermatitis; analyst expectations; Dupixent; EASI-75; market reaction

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

5 months ago talkbio0Tagged Automation, Cells, digital solutions, gene therapy, Growth, Logistics, Market, patient-specific therapies, risk mitigation, scalability, supply chain, white glove delivery

cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth